Why do ibs occur

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder affecting approximately 10-15% of the global population, with higher prevalence in women and younger adults. It is characterized by chronic abdominal pain and altered bowel habits (diarrhea, constipation, or both) without detectable structural abnormalities. The exact cause remains unknown but involves complex interactions between gut-brain axis dysfunction, visceral hypersensitivity, altered gut motility, and microbial imbalances. Diagnosis is typically based on the Rome IV criteria, established in 2016, which require symptoms for at least 6 months with onset at least 3 months prior.

Key Facts

IBS affects 10-15% of people worldwide, making it one of the most common gastrointestinal disorders.
Women are about twice as likely as men to develop IBS, with onset often occurring before age 50.
The Rome IV diagnostic criteria, updated in 2016, require recurrent abdominal pain at least 1 day per week for 3 months, associated with changes in stool frequency or form.
IBS costs the U.S. healthcare system an estimated $1.5-$10 billion annually in direct medical expenses.
Approximately 20-50% of IBS patients report symptom onset after an acute gastrointestinal infection, known as post-infectious IBS.

Overview

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder first described in medical literature in the early 19th century, though it gained formal recognition as a distinct condition in the 1950s. Historically, it was often mislabeled as "nervous colon" or "spastic colitis," reflecting early theories about its psychological origins. Today, IBS is classified into subtypes based on predominant stool pattern: IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), mixed IBS (IBS-M), and unsubtyped IBS. The disorder affects people of all ages but is most commonly diagnosed in individuals aged 20-40, with global prevalence studies showing rates ranging from 5% in some Asian countries to over 20% in Western nations. Despite its high prevalence, IBS remains underdiagnosed, with only about 30% of affected individuals seeking medical care, often due to stigma or mild symptoms. The economic burden is substantial, with indirect costs from lost productivity estimated to exceed direct medical costs in many countries.

How It Works

IBS involves complex pathophysiological mechanisms centered on the gut-brain axis, a bidirectional communication system between the central nervous system and the enteric nervous system. Key processes include visceral hypersensitivity, where the gut perceives normal stimuli as painful due to altered pain processing in the brain and spinal cord. Gut motility abnormalities lead to either accelerated transit (causing diarrhea) or delayed transit (causing constipation), often triggered by stress, diet, or hormonal changes. Microbial dysbiosis, characterized by imbalances in gut bacteria such as reduced Bifidobacterium and increased Firmicutes, contributes to inflammation and gas production. Immune system activation, with elevated levels of mucosal cytokines like interleukin-6, may play a role, particularly in post-infectious IBS. Additionally, serotonin dysregulation affects gut secretion and motility, as 95% of the body's serotonin is produced in the gut. These factors interact with psychological stressors, which can exacerbate symptoms through cortisol release and autonomic nervous system changes.

Why It Matters

IBS significantly impacts quality of life, with studies showing that patients report lower scores on health-related quality of life scales compared to those with diabetes or renal failure. It accounts for up to 12% of primary care visits and 28% of gastroenterology referrals, straining healthcare resources. Beyond individual suffering, IBS contributes to substantial economic losses through absenteeism and presenteeism, with U.S. estimates of indirect costs reaching $20 billion annually. Research into IBS has advanced understanding of the gut-brain connection, influencing treatments for other functional disorders and highlighting the importance of microbiome-targeted therapies. Effective management, including dietary approaches like the low FODMAP diet (developed in 2005) and psychological interventions, can reduce symptoms by 50-70% in responsive patients, demonstrating the value of integrated care models.